JPY 84.0
(-3.45%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 26 Million JPY | -54.28% |
2022 | 56.86 Million JPY | 834.17% |
2021 | 6.08 Million JPY | -94.53% |
2020 | 111.17 Million JPY | -32.46% |
2019 | 164.6 Million JPY | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 220.43 Million JPY | 2095.96% |
2024 Q1 | -11.04 Million JPY | 2.63% |
2023 Q4 | -11.34 Million JPY | -203.17% |
2023 FY | 26 Million JPY | -54.28% |
2023 Q3 | 10.99 Million JPY | 197.11% |
2023 Q2 | -11.32 Million JPY | -348.1% |
2023 Q1 | 4.56 Million JPY | -88.09% |
2022 Q4 | 38.32 Million JPY | 429.75% |
2022 FY | 56.86 Million JPY | 834.17% |
2022 Q3 | -11.62 Million JPY | 0.0% |
2021 FY | 6.08 Million JPY | -94.53% |
2020 FY | 111.17 Million JPY | -32.46% |
2019 FY | 164.6 Million JPY | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 99.947% |
Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 99.999% |
Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 99.986% |
Shionogi & Co., Ltd. | 369.08 Billion JPY | 99.993% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | 99.266% |
Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 99.973% |
Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 99.932% |
Eisai Co., Ltd. | 586.41 Billion JPY | 99.996% |
Morishita Jintan Co., Ltd. | 5.99 Billion JPY | 99.567% |
Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 99.967% |
Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 99.95% |
Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 99.808% |
Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | 99.664% |
Tsumura & Co. | 68.81 Billion JPY | 99.962% |
Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 99.93% |
Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 99.895% |
Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 99.968% |
Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 99.843% |
Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 99.948% |
KYORIN Holdings, Inc. | 51.4 Billion JPY | 99.949% |
Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | 97.59% |
Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | 99.736% |
SymBio Pharmaceuticals Limited | 4.41 Billion JPY | 99.411% |
Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | 99.676% |
Solasia Pharma K.K. | 337 Million JPY | 92.285% |
Modalis Therapeutics Corporation | -731 Thousand JPY | 3656.772% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 99.915% |
Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 99.952% |
Cyfuse Biomedical K.K. | 37.74 Million JPY | 31.115% |
Toho Holdings Co., Ltd. | 112.98 Billion JPY | 99.977% |
Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | 99.608% |